Safety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant Ascites

Inclusion Criteria: * patients who have completed 4 infusions of catumaxomab in the CASIMAS study * age \>= 18 years * Karnofsky index \>= 60 % * patients with malignant ascites requiring their first therapeutic ascites paracentesis after at least 60days following last catumaxomab infusion in the CASIMAS study * Patients where standard therapy is either not available or no longer feasible Exclusion Criteria: * acute or chronic infection * concomitant treatment with investigational products other than catumaxomab, cancer, chemo- or radiotherapy * previous treatment with entirely murine monoclonal antibodies other than catumaxomab * liver metastases with volume \>70 % of liver metastasized tissue